+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma



Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma



Liver Cancer 4(4): 253-262



Patients with intermediate-stage hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE) are considered to be candidates for sorafenib. The aim of this study was to evaluate the superiority of conversion of treatment to sorafenib on overall survival (OS) for cases refractory to TACE. This was a retrospective cohort study carried out on 497 patients with HCC who were treated with TACE therapy at our hospital between January 2008 and December 2013. Fifty-six patients were diagnosed as refractory to TACE during their clinical course and they were divided into two cohorts, (1) those who switched from TACE to sorafenib and (2) those who continued TACE. The overall survival (OS) after the time of being refractory to TACE was evaluated between the two groups. After refractoriness to TACE therapy was confirmed, 24 patients continued with TACE (TACE-group) and 32 patients underwent treatment conversion to sorafenib (sorafenib-group). The median OS was 24.7 months in the sorafenib-group and 13.6 months in the TACE-group (p=0.002). Conversion to sorafenib significantly improves the OS in patients refractory to TACE therapy with intermediate-stage HCC. Administration of sorafenib is therefore recommended in such circumstances of TACE treatment failure.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057714895

Download citation: RISBibTeXText

PMID: 26734579

DOI: 10.1159/000367743


Related references

Mo2028 Comparison Between Transcatheter Arterial Chemoembolization (Tace) and Transcatheter Arterial Chemoembolization Combined With Percutaneous Radiofrequency Ablation (Tace-Rfa) for Treatment of Intermediate Hepatocellular Carcinoma. Gastroenterology 144(5): S-722, 2013

P.13.7 Comparison Between Transcatheter Arterial Chemoembolization (Tace) And Transcatheter Arterial Chemoembolization Combined With Percutaneous Radiofrequency Ablation (Tace-Rfa) For Treatment Of Intermediate Hepatocellular Carcinoma (Hcc). Digestive and Liver Disease 45: S183-S184, 2013

Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. Plos One 9(6): E100305, 2015

Metronomic S-1 chemotherapy plus transcatheter arterial chemoembolization (TACE): a promising treatment of hepatocellular carcinoma refractory to TACE. Journal of BUON 21(4): 909-916, 2017

Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. International Journal of Cancer 132(10): 2448-2458, 2013

Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Journal of Gastroenterology 49(5): 932-940, 2015

Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma. Oncology 80(3-4): 188-194, 2011

Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. Anticancer Research 36(7): 3523-3529, 2017

Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology 87(6): 330-341, 2015

Comparison of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma. Oncology Reports 31(1): 65-72, 2014

Transcatheter Arterial Chemoembolization Plus 131 I-Labelled Metuximab versus Transcatheter Arterial Chemoembolization Alone in Intermediate/Advanced Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Korean Journal of Radiology 17(6): 882-892, 2017

Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib. Oncotarget 8(23): 37855-37865, 2016

Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis. Clinical Drug Investigation 35(11): 751-759, 2016

Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE. Contemporary Oncology 20(6): 468-474, 2017

Effects of kanglaite capsules combined with transcatheter arterial chemoembolization (TACE) on patients with mid or late-stage primary hepatocellular carcinoma (HCC). Chinese-German Journal of Clinical Oncology 8(2): 65-68, 2009